GEN Exclusives

More »

GEN News Highlights

More »
Jan 20, 2012

La Jolla Pharmaceutical Picks Up Solana’s Galectin-3 Antagonist

  • La Jolla Pharmaceutical acquired global development and commercialization rights to Solana Therapeutics’ inhibitor of galectin-3, GCS-100. Galectin-3 has been implicated in cancer and chronic organ failure.

    GCS-100's ongoing development as an anticancer and antifibrotic agent is supported by preclinical and clinical investigation including Phase I and Phase II trials involving more than 140 patients. Experimental results to date indicate that GCS-100 specifically inhibits galectin-3 in immune cells and confers anticancer activity in several tumor types.

    Galectin-3 plays a key role in the immune system's response to cancer and tissue injury. Investigators at the Ludwig Cancer Institute have reportedly shown that galectin-3 inhibits the activity of cancer-killing T cells and that pharmacologically blocking galectin-3 with GCS-100 reactivates these T cells. In addition, a number of other academic studies have concluded that galectin-3 is a mediator of fibrosis after heart, kidney, lung, and liver injury.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?